MedNous

A monthly publication providing critical insights into the business of medical innovation in Europe. Published in London, distributed by subscription worldwide.

[MedNous @MedNous]

@evotec bounces back after cyber attack in Q2. H1 revenue up by 14% from a year earlier. see @MedNous

[MedNous @MedNous]

@MorphoSys gives Q2 revenue, R&D data; awaits results of myelofibrosis trial. see @MedNous

[MedNous @MedNous]

The Jul-Aug 2023 edition of @MedNous with articles on the new EU patent and the use of real-world evidence in regulatory decision making is now out. For further information write to [email protected].

[MedNous @MedNous]

@AstraZeneca appoints Sharon Barr as executive vice president biopharmaceutials R&D effective 1 August. see @MedNous.

[MedNous @MedNous]

@argenxglobal raises $1.27 bln in global offering, after exercise of underwriters' options, to support pipeline of therapies for autoimmune diseases. see @MedNous

[MedNous @MedNous]

@Novartis advances plans for Sandoz spin-off; upgrades guidance for sales and core operating profit in 2023. see @MedNous

[MedNous @MedNous]

@NodThera reports positive data from small molecule drug being tested for Parkinson's disease. In volunteers, drug reduced neuroinflammatory biomarkers. see @MedNous

[MedNous @MedNous]

Write to [email protected] for a complimentary copy of the June edition of MedNous with articles on a preclinical project for Alzheimer's disease, a review of ASCO 2023 and an exclusive report on biotech incubation in the UK.

[MedNous @MedNous]

The May issue of @MedNous is now out featuring a review of proposed EU pharma legislation, new statistics on oncology drug development timelines and an interview with the radiopharmaceutical company @Ariceum_Tx. For a complimentary copy write to [email protected].

[MedNous @MedNous]

@AstraZeneca guides for revenue growth in 2023. see @MedNous

[MedNous @MedNous]

The April edition of @MedNous is now out with articles on HIV vaccine research, the development of a new antibacterial by @destinypharma and a discussion of p38 MAPK inhibition by Matthew Wright at Kinarus. For a complimentary copy, write to [email protected].

[MedNous @MedNous]

Alentis Therapeutics completes Series C financing of $105 mln to develop anti-claudin-1 antibodies, supported by @jeito_life and @novoholdings. see @MedNous

[MedNous @MedNous]

@Evotec rebounded in Q4 after strong performance of service business and income from partnerships. see @MedNous

[MedNous @MedNous]

The March edition of @MedNous is now available to subscribers. It features original research for type 2 diabetes, a review of the late-stage oncology drug pipeline and an interview with #Adrenomed on septic shock. For further information, write to [email protected].

[MedNous @MedNous]

#SiliconValleyBank shuttered; new bank set up by the FDIC. see @MedNous

[MedNous @MedNous]

@uniQure_NV rolls out gene therapy for haemophilia B. see @MedNous.

[MedNous @MedNous]

@Adaptimmune expands pipeline with acquisition of TCR2 Therapeutics Inc. see @MedNous

[MedNous @MedNous]

@intelliatx gene editing trial in HAE cleared to take place in US in addition to sites in the UK, New Zealand and the Netherlands. see @MedNous

[MedNous @MedNous]

@argenxglobal expects to report data from multiple trials of Vyvgart this year and in 2024. Vyvgart sales in 2022 were $400.7 mln. see @MedNous

[MedNous @MedNous]

@Bayer to install Bill Anderson as CEO on 1 June; group sales for 2022 were €50.7 billion, led by crop science. see @MedNous